Relieving the IP burden on ag research


CRISPR is cheap and easy enough to be employed in every lab not just by major ag-biotech companies. A serious roadblock standing in the way of researchers, however, threatened to limit the technology potential for plant breeding: intellectual property (IP) rights. The good news is that two major patent holders, DuPont Pioneer and the Broad Institute of MIT and Harvard, have agreed to create a joint licensing framework for genome editing in agriculture. As a result, academic researchers are allowed to use CRISPR on plants free of charge, while biotech companies interested in commercial ag applications have a simplified procedure to access to the tools they need. Continue reading

CRISPRing future harvests at DuPont

This slideshow requires JavaScript.

CRISPR is set to make its commercial debut in maize fields in 2020. The honor (and burden) of probing the market, as the first product developed with the revolutionary technique for genome editing, is up to a kind of corn called waxy for the appearance of its kernels. Its starch is almost entirely amylopectin and almost zero amylose. Conventional waxy varieties already available to farmers have some yield drag due to the undesirable genetic baggage introduced by breeding. Conversely, DuPont Pioneer researchers created a waxy version of their best corn without yield drag or foreign DNA by editing out a gene for an enzyme that produces amylose. Amylopectin is used for the production of goods such as paper adhesives and food thickeners. What remains after its extraction is a protein flour that can be employed as feed. It may sound like a low-profile debut for the celebrated genome editing technology that is asked to succeed where GMOs have failed: gaining consumer confidence. But this is a deliberate strategy, as explained below by Neal Gutterson, DuPont Pioneer’s vice president of R&D. Continue reading